EDIT
Editas Medicine Inc
2.70$
-7.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.2% | 87.9% | 97.1% | 81.7% | 89.0% | 89.2% | 91.1% | 73.2% | 74.9% | 69.4% | 68.3% | 84.7% | 87.9% | |
| 81.1% | 87.2% | 95.9% | 80.9% | 39.3% | 32.1% | 46.8% | 24.4% | 30.0% | 27.5% | 24.8% | 38.5% | 78.6% | |
| 81.1% | 87.2% | 95.9% | 80.9% | 88.2% | 87.8% | 89.8% | 70.2% | 73.8% | 66.9% | 64.7% | 79.0% | 78.6% | |
| – | 8.4% | 0.7% | 0.0% | 0.2% | 0.0% | 0.1% | 1.1% | 0.0% | 1.0% | 2.0% | 4.8% | 8.1% | |
| – | – | 0.5% | 0.7% | 0.5% | 0.7% | – | -19.2% | -17.7% | -18.1% | – | – | – | |
| 2.1% | 9.1% | 1.4% | 17.6% | 10.6% | 9.6% | 7.8% | 2.4% | 2.5% | 3.0% | – | – | – | |
| – | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 171.1% | 225.5% | 155.6% | 41.3% | 44.3% | 43.8% | 48.4% | 31.3% | 18.3% | 29.9% | 30.1% | 60.7% | 85.4% | |
| 85.8% | 50.5% | 4.6% | 14.4% | 9.8% | 8.5% | 11.8% | 10.2% | 6.9% | 11.7% | 12.7% | 22.6% | 24.8% | |
| – | 0.5% | 6.7% | 4.4% | 2.0% | 3.0% | 1.1% | 1.2% | 1.5% | 2.2% | 4.8% | 4.3% | 5.9% | |
| 16.3% | 21.3% | 0.9% | 2.0% | 1.1% | 1.3% | 1.1% | 1.1% | 0.7% | 1.8% | 1.7% | 1.6% | 1.4% | |
| – | 2.8% | 23.5% | 15.3% | 9.0% | – | – | – | – | – | – | – | – | |
| -71.1% | -125.5% | -55.6% | 58.7% | 55.7% | 56.2% | 51.6% | 68.7% | 81.7% | 70.1% | 69.9% | 39.3% | 14.6% | |
| -71.1% | -126.7% | -59.1% | -81.0% | -81.9% | -99.0% | -107.9% | -116.2% | -126.6% | -209.6% | -246.7% | -429.9% | -873.0% | |
| 1,211.1% | 21.0% | 23.9% | 14.1% | 10.8% | 11.2% | 9.8% | 10.2% | 10.0% | 13.4% | 15.2% | 24.1% | 47.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.